IVIG

From newsworthy moments to groundbreaking research, these are the most popular articles in the intravenous immunoglobulin space, published on Pharmacy Times® during 2022.

Treatment observably eased obsessive-compulsive disorder symptom severity in young patients, however, symptoms still caused students to be absent from school at least 2 days every month.

Although patients with Richter syndrome often experience poor outcomes, there are many new treatment strategies that have demonstrated a durable response.

A patient with juvenile dermatomyositis experienced aseptic meningitis brought on by intravenous immunoglobulin and recovered fully with no neurological effects.

Mice receiving prophylactic recombinant factor FVIII and intravenous immunoglobulin for hemophilia A had reduced anti-FVIII antibodies versus mice who received FVIII only.

New system may more accurately identify IVIG resistance in North American patients with Kawasaki disease than the Kobayashi score.

Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series.

Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.

Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.

Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.

Automation can lessen the administrative burden on providers and accelerate specialty prescribing and dispensing to provide patients with quality care the moment they need it.

Study data showed that more than three-quarters of patients with dermatomyositis who received intravenous immune globulin therapy experienced improved symptoms.

Intravenous immunoglobulin was more effective than placebo, but not more effective than plasmapheresis and corticosteroids.

Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.

A new cell isolation kit was approved by the FDA to decrease the amount of time needed in a lab and lower overall costs for testing tuberculosis.

Although there is no “best” way to determine which route of administration is best, health care providers are optimally positioned to educate patients and help them make the best decision.

Asceniv is a plasma-derived polyclonal IVIG drug product designed to prevent serious bacterial infections in patients with primary humoral immunodeficiency disease.

Complete recovery of platelet counts after obinutuzumab-based therapy was found to be associated with, or accelerated by, intravenous immunoglobulin.

Though there is no well-defined therapeutic approach to the treatment of Arndt-Gottron syndrome, intravenous immunoglobulins have been documented as a well-tolerated treatment in some cases.

There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Researchers recommend having a low clinical threshold for the diagnosis of Hashimoto’s encephalopathy in patients who reveal no apparent cause for their altered mental status, given the heterogenous nature of the condition’s presentation.

Patients with past medical histories of immunoglobulin E-mediated hypersensitivity reactions to metronidazole and other antimicrobial agents may receive safe and effective treatment using desensitization protocols.

Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.

A recent case report detailing multiple procedures and inconclusive biopsies underwent by a patient with unusual presentation of immunoglobulin G4-related disease before conclusive diagnosis emphasizes the importance of follow-up with patients with suspicion of systemic disease.

Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma.

Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.

Current development efforts in IVIG are focused on new routes of administration for immunoglobulin that can overcome the limitations of intramuscular administration.

Dosing recommendations for patients requiring ECMO support are unlikely to be supported by high-quality evidence, but are usually extrapolated from the physicochemical characteristics of individual drugs in conjunction with data from pharmacokinetic studies and case reports.